Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

TEL AVIV, Israel, Aug. 31, 2026 — Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference. Dr. Mor’s prerecorded presentation will be webcast and will be available starting on September 11, 2026 at 7:00 am ET. The link to access the webcast is included below and is also available at the Events section of the Chemomab website.

Dr. Mor and Dr. Reg Seeto, Chief Executive Officer of Scipher Medicine Corporation (Scipher), will be attending the H.C. Wainwright Conference in New York City in person and will be co-hosting 1x1 investor meetings September 14-16, 2026. On July 8, 2026 Chemomab and Scipher announced a definitive merger agreement, which is expected to close before year-end. Based on its pioneering work in immunology precision medicine, Scipher plans to advance Chemomab’s first-in-class anti-CCL24 antibody nebokitug into a Phase 2 trial in rheumatoid arthritis, a $24 billion market opportunity with substantial unmet need.

Chemomab Presentation at H.C. Wainwright 28th Annual Global Investment Conference

Date:

September 11, 2026

Time:

Available starting at 7:00 am ET for 90 days

Format:

Prerecorded webcast presentation

Webcast Link:

https://journey.ct.events/view/ef4e7ef6-a1dd-461a-9656-29523cdc694d

For information on attending the 2026 H.C. Wainwright Global Investment Conference, contact your representative or click here.

About Chemomab Therapeutics Ltd.

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening immune-fibrotic diseases. Chemomab has reported positive results from five clinical trials of nebokitug, including the Phase 2 SPRING trial in patients with primary sclerosing cholangitis. For more information, visit: chemomab.com.

About Scipher Medicine

Scipher Medicine is driving the probability of success at each stage of drug development from discovery to commercialization by leveraging AI with network biology and proprietary data, through its SPECTRA™ and associated data platforms. Scipher has one of the industry’s largest RA genomic data assets and biobanks in addition to electronic medical record data for more than 3 million rheumatology patients. It developed and markets PrismRA®, a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects more than 20 million patients globally. For more information, visit www.sciphermedicine.com

Contact

Media and Investors: Barbara Lindheim Consulting Vice President, Investor & Public Relations, Strategic Communications Phone: +1 917-355-9234 [email protected] [email protected]